Mark McBriar Ph.D., Marisa Sanders Ph.D. On June 30, 2025, the Federal Circuit issued a precedential decision in Eye Therapies, LLC v. Slayback Pharma, LLC,[1] reversing the Patent Trial and Appeal ...
Sound Understanding of the Patent Landscape Remains Crucial to Bringing a Drug to Market In patent law, the claim is the name of the game. For emerging and established biotechnology and pharmaceutical ...
Government investigations are costly, requiring companies and individuals to expend significant financial resources to comply with, or challenge, the government’s requests. In these situations, where ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
“The CAFC agreed with the Board, explaining that the phrase ‘Identifying a single biomolecule’ has an ordinary meaning ‘on its face and in context.’ The U.S. Court of Appeals for the Federal Circuit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results